Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01627340




Registration number
NCT01627340
Ethics application status
Date submitted
21/06/2012
Date registered
25/06/2012
Date last updated
31/07/2018

Titles & IDs
Public title
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus
Scientific title
An Open-label Study to Assess the Immunogenicity and Safety of GSK Biologicals' Hepatitis B Vaccine, Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus
Secondary ID [1] 0 0
115918
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hepatitis B 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Metabolic and Endocrine 0 0 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Engerix™-B vaccine

Experimental: Diabetes Group - Subjects diagnosed with type 2 diabetes within the five year period before study start who received 3 doses of Engerix™-B vaccine (HBV) at 0, 1 and 6 months. The vaccine was administered intramuscularly (IM) into the deltoid region of the non-dominant arm.

Active Comparator: Control Group - Subjects with no diagnosis or documented history of diabetes who received 3 doses of Engerix™-B (HBV) vaccine at 0, 1 and 6 months. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.


Other interventions: Engerix™-B vaccine
3 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Subjects Seroprotected for Anti- Hepatitis B Surface Antigen (Anti-HBs) Antibodies
Timepoint [1] 0 0
At one month after the third dose of primary vaccination (Month 7)
Secondary outcome [1] 0 0
Anti-HBs Antibody Concentration
Timepoint [1] 0 0
At one month after the third dose of primary vaccination (Month 7)
Secondary outcome [2] 0 0
Number of Subjects Reporting Any Solicited Local Symptoms
Timepoint [2] 0 0
During the 4-day (Days 0-3) post-vaccination period
Secondary outcome [3] 0 0
Number of Subjects Reporting Any Solicited General Symptoms
Timepoint [3] 0 0
During the 4-day (Days 0-3) post-vaccination period
Secondary outcome [4] 0 0
Number of Subjects Reporting Any Unsolicited Adverse Events (AEs)
Timepoint [4] 0 0
During the 31-day (Days 0-30) post-vaccination period
Secondary outcome [5] 0 0
Number of Subjects Reporting Any Serious Adverse Events (SAEs)
Timepoint [5] 0 0
During the entire study period (Month 0 - Month 7)

Eligibility
Key inclusion criteria
All subjects must satisfy ALL the following criteria at study entry:

- Subjects who, in the opinion of the investigator, can and will comply with the
requirements of the protocol.

- A male or female subject aged 20 years and above at the time of screening.

- Written informed consent obtained from the subject at screening.

- Subjects diagnosed with type 2 diabetes documented within the past five years,
according to the criteria specified by the American Diabetes Association or currently
taking any form of anti-diabetic intervention documented by the investigator; or
control subjects with no diagnosis or documented history of diabetes, and HbA1c less
than 6.5%, as determined by laboratory screening tests.

- Normal renal function defined as estimated glomerular filtration rate (GFR) = 50
mL/min, estimated through the Modification of Diet in Renal Disease (MDRD) or the
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, as determined by
laboratory screening tests.

- Seronegative for hepatitis B surface antigen (HBsAg), anti-HBs antibodies and
antibodies to hepatitis B core antigen (anti HBc), as determined by laboratory
screening tests.

- Female subjects of non-childbearing potential may be enrolled in the study.

- Non-childbearing potential is defined as pre-menarche, current tubal ligation,
hysterectomy, ovariectomy or post-menopause.

- Female subjects of childbearing potential may be enrolled in the study, if the
subject:

- has practiced adequate contraception for 30 days prior to vaccination, and

- has a negative pregnancy test on the day of screening and at Visit 1, and

- has agreed to continue adequate contraception during the entire treatment period
and for two months after completion of the vaccination series.
Minimum age
20 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
The following criteria should be checked at the time of study entry. If ANY exclusion
criterion applies, the subject must not be included in the study:

- Use of any investigational or non-registered product other than the study vaccine
within 30 days preceding the first dose of study vaccine, or planned use during the
study period.

- Chronic administration of immunosuppressants or other immune-modifying drugs within
six months prior to the first vaccine dose.

- Administration of long-acting immune-modifying drugs within 6 months of the study
entry or planned administration at any time during the study period.

- Administration of a vaccine not foreseen by the study protocol starting from 30 days
before each dose of vaccine and ending 30 days after each dose, with the exception of
the inactivated influenza vaccine which is allowed at any time during the study if
administered at a separate site.

- Concurrently participating in another clinical study, at any time during the study
period, in which the subject has been or will be exposed to an investigational or a
protocol-specified non-investigational product.

- Any previous complete or incomplete vaccination against hepatitis B since birth.

- Any confirmed or suspected immunosuppressive or immunodeficient condition, including
HIV infection, based on medical history and physical examination.

- History of any reaction or hypersensitivity likely to be exacerbated by any component
of the vaccine, including latex.

- Advanced heart failure or any other severe clinical condition that significantly
reduces the subject's life expectancy.

- Acute disease and/or fever at the time of enrolment.

- Administration of immunoglobulins and/or any blood products within the three months
preceding the first dose of study vaccine or planned administration during the study
period.

- Any history of alcohol or drug abuse in the past 5 years.

Study design
Purpose of the study
Prevention
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 4
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
24/07/2012
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
18/12/2013
Sample size
Target
Accrual to date
Final
667
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Recruitment hospital [1] 0 0
GSK Investigational Site - Herston
Recruitment hospital [2] 0 0
GSK Investigational Site - Box Hill
Recruitment hospital [3] 0 0
GSK Investigational Site - St Albans
Recruitment postcode(s) [1] 0 0
4029 - Herston
Recruitment postcode(s) [2] 0 0
3128 - Box Hill
Recruitment postcode(s) [3] 0 0
3021 - St Albans
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Georgia
Country [3] 0 0
United States of America
State/province [3] 0 0
Idaho
Country [4] 0 0
United States of America
State/province [4] 0 0
Indiana
Country [5] 0 0
United States of America
State/province [5] 0 0
Kansas
Country [6] 0 0
United States of America
State/province [6] 0 0
New York
Country [7] 0 0
United States of America
State/province [7] 0 0
Ohio
Country [8] 0 0
United States of America
State/province [8] 0 0
Tennessee
Country [9] 0 0
United States of America
State/province [9] 0 0
Utah
Country [10] 0 0
United States of America
State/province [10] 0 0
Washington
Country [11] 0 0
Canada
State/province [11] 0 0
Nova Scotia
Country [12] 0 0
Canada
State/province [12] 0 0
Ontario
Country [13] 0 0
Canada
State/province [13] 0 0
Quebec
Country [14] 0 0
New Zealand
State/province [14] 0 0
Hamilton
Country [15] 0 0
New Zealand
State/province [15] 0 0
Rotorua
Country [16] 0 0
New Zealand
State/province [16] 0 0
Takapuna Auckland
Country [17] 0 0
New Zealand
State/province [17] 0 0
Wellington

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study will evaluate the immunogenicity and safety of Engerix™-B (hepatitis B vaccine)
when administered as a primary vaccination course at 0, 1 and 6 months in adults with or
without type 2 diabetes mellitus.
Trial website
https://clinicaltrials.gov/ct2/show/NCT01627340
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01627340